With a one year PEG ratio of 383.29, Medpace Holdings Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 90.48% of US stocks.
MEDP's went public 3.99 years ago, making it older than merely 14.02% of listed US stocks we're tracking.
With a year-over-year growth in debt of 162.93%, Medpace Holdings Inc's debt growth rate surpasses 91.44% of about US stocks.
Stocks that are quantitatively similar to MEDP, based on their financial statements, market capitalization, and price volatility, are TTGT, CBPO, EVR, IMAX, and MC.
MEDP's SEC filings can be seen here. And to visit Medpace Holdings Inc's official web site, go to www.medpace.com.
Medpace, Inc. operates as a contract research organization that provides research based drug and medical device development services. The company was founded in 1992 and is based in Cincinnati, Ohio.
MEDP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Medpace Holdings Inc. To summarize, we found that Medpace Holdings Inc ranked in the 47th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Medpace Holdings Inc ended up being:
The company's balance sheet shows it gets 98% of its capital from equity, and 2% of its capital from debt. Notably, its equity weight is greater than 82.27% of US equities in the Healthcare sector yielding a positive free cash flow.
The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately merely 9.49% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Medpace Holdings Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -271.12. This coverage rate is greater than that of merely 0.74% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
DXCM, HRC, STE, AMGN, and EDAP can be thought of as valuation peers to MEDP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Medpace ([[MEDP]] +8.1%) reported Q2 revenue of $205M, ahead of consensus by $23.8M, with a backlog conversion rate of 15.8%.Net income of $24.1M or $0.64/share, beating consensus by $0.28.Net new business awards stood at $254.1M, 9% Y/Y drop leading to net book-to-bill ratio of 1.24x.EBITDA was down 12.9% to $35M.As of...